Cypress Pharmaceutical, Pernix Therapeutics deal

Pernix completed its acquisition of generics company Cypress and its Hawthorn Pharmaceuticals Inc. branded pharmaceutical subsidiary for $102 million comprising $52 million upfront, $34 million in sh...